

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 9/20, 31/165	A2	(11) International Publication Number: WO 98/38983
		(43) International Publication Date: 11 September 1998 (11.09.98)

(21) International Application Number: PCT/EP98/01284

(22) International Filing Date: 27 February 1998 (27.02.98)

(30) Priority Data:  
9704524.9 5 March 1997 (05.03.97) GB(71) Applicant (for all designated States except US): SMITHKLINE  
BEECHAM PLC [GB/GB]; New Horizons Court, Brentford,  
Middlesex TW8 9EP (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): GRATTAN, Timothy,  
James [GB/GB]; SmithKline Beecham Consumer Health-  
care, St. George's Avenue, Weybridge, Surrey KT13 0DE  
(GB).(74) Agent: THOMPSON, Clive, Beresford; SmithKline Beecham  
plc, Corporate Intellectual Property, Two New Horizons  
Court, Brentford, Middlesex TW8 9EP (GB).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO  
patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG).**Published***Without international search report and to be republished  
upon receipt of that report.*

(54) Title: SWALLOW TABLET COMPRISING PARACETAMOL

## (57) Abstract

A swallow tablet or capsule formulation is described comprising paracetamol, sodium bicarbonate and at least one pharmaceutically acceptable excipient.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## SWALLOW TABLET COMPRISING PARACETAMOL

The present invention relates to pharmaceutical compositions containing N-aceryl-p-aminophenol, known by the generic names paracetamol, acetaminophen and APAP (hereinafter referred to as paracetamol). In particular, the invention relates to a fast acting paracetamol formulation in the form of a swallow tablet or capsule which has a greatly improved rate of absorption following ingestion by the patient.

Paracetamol is an analgesic and antipyretic agent which is widely used in prescription and non-prescription medicines, often in combination with other biologically active compounds. Following ingestion of paracetamol in a solid form, such as a tablet or capsule, the rate of absorption and hence the onset of pharmacological activity has been found to vary from patient to patient and can sometimes be very slow.

Many attempts have been made to improve the rate of onset of activity, for example by speeding up the disintegration of tablets by making effervescent formulations.

United Kingdom patent publication GB 2 103 087 (Bristol-Myers) describes an analgesic composition containing paracetamol that has an increased rate of absorption. GB 2 103 087 refers to a publication (J. Wojcicki et al, Zbl. Pharm., 118, (1979), Vol 2-3) describing investigations into the pharmacokinetics of paracetamol in which a single oral dose of 1000 mg of paracetamol was administered with 4000 mg of antacid in the form of calcium carbonate. According to the reference in GB 2 103 087, the combination was found to decrease the rate of absorption of paracetamol, when compared with the rate of absorption from paracetamol (1000 mg ) alone.

According to GB 2 103 087, an improved rate of absorption is achieved by co-administering a therapeutic dose comprising from about 150 mg to about 2000 mg of paracetamol with from about 60 mg to about 1200 mg of an antacid. The publication states that any antacid or combinations thereof commonly used to neutralise stomach acids may be used. GB 2 103 087 identifies antacids of special interest to be calcium carbonate, magnesium carbonate, a combination of calcium

carbonate and magnesium carbonate, sodium bicarbonate and magnesium hydroxide. GB 2 103 087 exemplifies compositions comprising combinations of paracetamol with calcium carbonate, with a mixture of calcium carbonate and magnesium carbonate and with sodium bicarbonate.

5       The examples in GB 2 103 087 include two tablet formulations containing paracetamol and sodium bicarbonate: one such formulation comprises 325 mg of paracetamol and 225 mg of sodium bicarbonate wherein the weight ratio of sodium bicarbonate to paracetamol is 0.69 to 1, and the second formulation comprises 500  
10       mg of paracetamol and 225 mg of sodium bicarbonate wherein the weight ratio of sodium bicarbonate to paracetamol is 0.4 to 1. When the various formulations exemplified in GB 2 103 087 were administered to healthy volunteers it was found that, for all the formulations tested, the actual increase in rate of absorption, was between 7 and 31% compared to conventional paracetamol tablets.

      It has now been found unexpectedly that by selecting sodium bicarbonate and  
15       combining it with paracetamol in a tablet or capsule formulation such that it is present in an amount of at least 300 mg per tablet and the weight ratio of bicarbonate to paracetamol is at least 0.74 to 1, a swallow tablet or capsule can be produced which gives a statistically significant improvement in the rate of  
20       absorption over that obtained from a commercially available paracetamol tablet containing no sodium bicarbonate. This improvement is not observed when other antacids, eg. calcium carbonate, are combined with paracetamol in a solid dosage form at equivalent levels. More surprisingly, the rate of absorption following oral  
25       administration of such a solid dosage form comprising paracetamol and sodium bicarbonate also shows an improvement over that obtained following oral administration of an aqueous solution of a commercially available soluble product  
30       containing paracetamol and sodium bicarbonate. In the context of the present invention, an increase in the rate of absorption may be demonstrated as an increased in  $C_{max}$ , where  $C_{max}$  is the maximum concentration of paracetamol in the serum, or by measuring the area under the concentration vs time curve in the first 20 minutes after dosing ( $AUC_{0-20}$ ) when compared with other paracetamol compositions.

      According to the present invention there is provided a swallow tablet or capsule formulation comprising from 300mg to 600mg of paracetamol and from

300mg to 1200mg of sodium bicarbonate wherein the weight ratio of sodium bicarbonate to paracetamol is at least 0.74 to 1.

For the avoidance of doubt, a swallow tablet is a tablet which is intended to be swallowed whole and not one which is intended for dissolution or suspension in water prior to administration, for example a tablet containing a substantial amount of an effervescent couple.

The tablet or capsule formulation of the invention preferably contains either 325 mg or 500 mg of paracetamol. The amount of sodium bicarbonate present in the formulation is favourably at least 370 mg, eg at least 400 mg or 500 mg and suitably is no greater than 1000 mg, preferably no greater than 800 mg and more preferably no greater than 700 mg. The weight ratio of sodium bicarbonate to paracetamol is favourably at least 0.8 to 1, preferably at least 1 to 1, and more preferably at least 1.25 to 1.

Formulations of the invention will generally contain at least one pharmaceutically acceptable excipient conventionally used in the art of tablet and/or capsule formulation. Suitable excipients which may be incorporated include lubricants, for example magnesium stearate and stearic acid; disintegrants, for example cellulose derivatives; starches; binders, for example modified starches and cellulose derivatives; glidants, for example colloidal silicas; compression aids, for example cellulose derivatives; as well as preservatives, suspending agents, wetting agents, flavouring agents, bulking agents, adhesives, colouring agents, sweetening agents appropriate to their form.

In addition to paracetamol, sodium bicarbonate and a pharmaceutically acceptable excipient, formulations of the invention may also contain other pharmaceutically active agents, for example other analgesics, anti-inflammatory analgesic agents, decongestants, antihistamines, antitussive agents, etc.. Formulations may also contain a pharmaceutically acceptable analgesic adjuvant, for example caffeine.

The invention also provides a process for the preparation of the tablet or capsule formulation of the invention, which process comprises the admixture of paracetamol and sodium bicarbonate together with any pharmaceutically acceptable excipients, additional pharmaceutically acceptable active agents or adjuvants. Thus

the paracetamol and sodium bicarbonate may be mixed together with one or more binders and granulated using water. The resulting granule may then be dried, sieved and mixed with additional excipients such as a lubricant and disintegrant before being compressed into tablets. Alternatively, the sodium bicarbonate may be omitted from the granulation step and subsequently added with the other excipients. In an alternative process, tablets may be prepared using direct compression grades of paracetamol including commercially available forms which obviates the need for a granulation step. Tablets may also be prepared by other processes known in the art such as by shaping of an extruded mixture. For capsule production, the paracetamol and sodium bicarbonate may be mixed and granulated as for tablet production and filled into suitably sized capsule shells to the desired fill weight.

As stated above, the formulations according to the invention have an increased  $C_{max}$ , where  $C_{max}$  is the maximum concentration of paracetamol in the serum, when compared with other paracetamol compositions. Comparative experiments have demonstrated an increased  $C_{max}$  with respect to that obtained not only from swallow tablets containing only paracetamol or paracetamol plus calcium carbonate but also from proprietary soluble paracetamol formulations. Furthermore the formulations according to the invention have an increased ( $AUC_{0-20}$ ), indicating an increased rate of absorption of paracetamol, when compared to conventional paracetamol swallow tablets.

Indeed, the plasma profile for the paracetamol formulations in accordance with the present invention is comparable to that expected to be achieved with a dose of paracetamol administered intravenously. (Seymore R A, European J. Clin. Pharmacol., 20, 215-218, (1981), quotes 23.7 mg/litre in blood plasma following a 1000 mg iv dose of paracetamol.) Intravenous dosing of drugs is generally recommended in order to achieve a rapid maximum therapeutic effect which is not obtainable via oral dosing. However, intravenous dosing can be both painful and inconvenient. Moreover, since for a drug such as paracetamol which has poor solubility, intravenous formulations are not generally available, the present invention accordingly offers considerable practical benefit.

Furthermore, the addition of sodium bicarbonate in the weight ratio of the present invention has the potential added advantage that it may reduce the potential

for patients to suffer toxic effects of paracetamol overdose, which can have fatal consequences or, at the very least, lead to irreversible liver damage. An intake of about 40 paracetamol tablets containing 500mg paracetamol usually causes serious liver damage and sometimes proves fatal. The emetic dose of sodium bicarbonate is such that for most patients it would be achieved after swallowing tablets of the present invention well before the intake of paracetamol reaches a level that would prove fatal.

Another potential advantage of the formulations of the present invention is in the treatment of migraine. Proprietary products, for the alleviation of migraine headaches, which contain paracetamol also contain ingredients such as for example metaclopramide which is included to overcome the gastric stasis which accompanies migraine and promote gastric emptying in order to increase serum levels of paracetamol. Such ingredients can result in undesirable side effects. The formulations of the present invention which have an unexpectedly increased rate of absorption and thus obviate the need for additional ingredients carrying side effects, are clearly of benefit.

The following Examples (1 to 10) are illustrations of the invention. Comparative Example A is outside the scope of the invention but is included to further demonstrate the advantages of the invention.

#### Example 1

A granule suitable for compression into tablets was prepared from the following ingredients

25

<u>ingredient</u>	<u>mg/tablet</u>	<u>batch size (g)</u>
1. paracetamol (fine)	500.00	9000.00
2. sodium bicarbonate (fine)	630.00	11340.00
3. starch (maize)	11.40	205.20
4. starch (pregelatinised)	50.00	900.00
5. Povidone K25	2.00	36.00
6. potassium sorbate	0.60	10.80

Ingredients 1-6 were sieved through a 16 mesh sieve into a suitable mixer and granulated with a suitable quantity of deionised water to form a medium/heavy granule. The granule was dried in a suitable oven at 45°C, until the water content was

<1%. The resulting dried granule was then passed through a 12 mesh sieve to give a white granule (yield 20.250kg)

## 5 Example 2

Tablets were prepared from the following ingredients:

<u>ingredient</u>	<u>mg/tablet</u>	<u>batch size (g)</u>
1. granule from example 1	1194.00	19104.00
2. starch (maize)	10.00	160.00
3. talc	15.00	240.00
4. stearic acid	5.00	80.00
5. Acdisol	36.70	587.20
Total	1260.70	20171.20

10

Ingredients 1-5 were sieved through a 16 mesh sieve into a suitable blender and mixed. The resulting blend was then compressed into tablets using suitable capsule shaped tooling to give white capsule shaped tablets (target weight of 1260.7mg). The final composition of the tablets was as follows:

15

<u>ingredient</u>	<u>mg/tablet</u>
1. paracetamol (fine)	500.00
2. sodium bicarbonate (fine)	630.00
3. starch (maize)	21.40
4. starch (pregelatinised)	50.00
5. Povidone K25	2.00
6. potassium sorbate	0.60
7. talc	15.00
8. stearic acid	5.00
9. Acdisol	36.70
Total	1260.70

20

Each tablet contained paracetamol 500mg and sodium bicarbonate 630mg, with a ratio of sodium bicarbonate: paracetamol of 1.26 : 1



**Example 3**

- 5 Tablets (target weight 1023.82mg) were prepared by a similar method to than described in examples 1 and 2, but using different levels of ingredients such that the final formula was as follows:

<u>ingredient</u>	<u>mg/tablet</u>
1. paracetamol (fine)	500.00
2. sodium bicarbonate (fine)	400.00
3. starch (maize)	21.40
4. starch (pregelatinised)	50.00
5. Povidone K25	2.00
6. potassium sorbate	0.60
7. talc	15.00
8. stearic acid	5.00
9. Acdisol	29.82
Total	1023.82

- 10 Each tablet contained paracetamol 500mg and sodium bicarbonate 400mg, with a ratio of sodium bicarbonate: paracetamol of 0.8 : 1

**Example 4**

- 15 Tablets (target weight 993.82mg) are prepared by a similar method to that described in examples 1 and 2, but using different levels of ingredients such that the final formula is as follows:

<u>ingredient</u>	<u>mg/tablet</u>
1. paracetamol (fine)	500.00
2. sodium bicarbonate (fine)	370.00
3. starch (maize)	21.40
4. starch (pregelatinised)	50.00
5. Povidone K25	2.00
6. potassium sorbate	0.60
7. talc	15.00
8. stearic acid	5.00
9. Acdisol	29.82
Total	993.82

- 20 Each tablet contains paracetamol 500mg and sodium bicarbonate 370mg, with a ratio of sodium bicarbonate: paracetamol of 0.74 : 1

**Example 5**

- 5     Tablets (target weight 1430.7mg) are prepared by a similar method to that described in examples 1 and 2, but using different levels of ingredients such that the final formula is as follows:

<u>ingredient</u>	<u>mg/tablet</u>
1. paracetamol (fine)	500.00
2. sodium bicarbonate (fine)	800.00
3. starch (maize)	21.40
4. starch (pregelatinised)	50.00
5. Povidone K25	2.00
6. potassium sorbate	0.60
7. talc	15.00
8. stearic acid	5.00
9. Acdisol	36.70
Total	1430.70

- 10     Each tablet contains paracetamol 500mg and sodium bicarbonate 800 mg, with a ratio of sodium bicarbonate: paracetamol of 1.6 : 1

**Example 6**

- 15     Tablets (target weight 923.82mg) are prepared by a similar method to that described in examples 1 and 2, but using different levels of ingredients such that the final formula is as follows:

<u>ingredient</u>	<u>mg/tablet</u>
1. paracetamol (fine)	400.00
2. sodium bicarbonate (fine)	400.00
3. starch (maize)	21.40
4. starch (pregelatinised)	50.00
5. Povidone K25	2.00
6. potassium sorbate	0.60
7. talc	15.00
8. stearic acid	5.00
9. Acdisol	29.82
Total	923.82

- 20     Each tablet contains paracetamol 400mg and sodium bicarbonate 400mg, with a ratio of sodium bicarbonate: paracetamol of 1 : 1

Example 7

Tablets (target weight 1223.82mg) are prepared by a similar method to that described in examples 1 and 2, but using different levels of ingredients such that the final formula is as follows:

<u>ingredient</u>	<u>mg/tablet</u>
1. paracetamol (fine)	600.00
2. sodium bicarbonate (fine)	500.00
3. starch (maize)	21.40
4. starch (pregelatinised)	50.00
5. Povidone K25	2.00
6. potassium sorbate	0.60
7. talc	15.00
8. stearic acid	5.00
9. Acdisol	29.82
Total	1223.82

Each tablet contains paracetamol 600mg and sodium bicarbonate 500mg, with a ratio of sodium bicarbonate: paracetamol of 0.83 : 1

Example 8

Tablets (target weight 819.46mg) are prepared by a similar method to that described in examples 1 and 2, but using different levels of ingredients such that the final formula is as follows:

<u>ingredient</u>	<u>mg/tablet</u>
1. paracetamol (fine)	325.00
2. sodium bicarbonate (fine)	409.50
3. starch (maize)	13.91
4. starch (pregelatinised)	32.50
5. Povidone K25	1.30
6. potassium sorbate	0.39
7. talc	9.75
8. stearic acid	3.25
9. Acdisol	23.86
Total	819.46

Each tablet contains paracetamol 325mg and sodium bicarbonate 409.5mg, with a ratio of sodium bicarbonate to paracetamol of 1.26 : 1

**Example 9**

- 5     Tablets (target weight 1291.56mg) are prepared by blending ingredients 1 to 7 together and compressing using a suitable tablet press:

<u>Ingredient</u>	<u>mg/tablet</u>
1. paracetamol direct compression grade (90%)	555.56
2. sodium bicarbonate	630.00
3. microcrystalline cellulose	50.00
4. Explotab (Na Starch Glycolate)	25.00
5. Crosspovidone XL10	25.00
6. sodium lauryl sulfate	3.00
7. magnesium stearate	3.00
Total	1291.56

- 10     Each tablet contains paracetamol 500mg and sodium bicarbonate 630mg, with a ratio of sodium bicarbonate to paracetamol of 1.26 : 1

**Example 10**

- 15     Capsules are prepared as follows:

The granulation, sieving and blending steps from examples 1 and 2 are repeated. The resulting powder is then filled into hard gelatin capsules with a target fill weight of 819.46mg, such that the final formula is as follows:

20

<u>ingredient</u>	<u>mg/capsule</u>
1. paracetamol (fine)	325.00
2. sodium bicarbonate (fine)	409.50
3. starch (maize)	13.91
4. starch (pregelatinised)	32.50
5. Povidone K25	1.30
6. potassium sorbate	0.39
7. talc	9.75
8. stearic acid	3.25
9. Acdisol	23.86
Total	819.46

Each capsule contains paracetamol 325mg and sodium bicarbonate 409.5mg, with a ratio of sodium bicarbonate to paracetamol of 1.26 : 1

Comparative Example A

- 5 Tablets (target weight 988.23mg) were prepared by a similar method to that described in examples 1 and 2, but using different levels of ingredients and substituting calcium carbonate for sodium bicarbonate, such that the final formula was as follows:

<u>ingredient</u>	<u>mg/dose</u>
1. paracetamol (fine)	500.00
2. calcium carbonate	375.00
3. starch (maize)	21.40
4. starch (pregelatinised)	50.00
5. Povidone K25	2.00
6. potassium sorbate	0.60
7. talc	15.00
8. stearic acid	5.00
9. Acdisol	19.23
<b>Total</b>	<b>988.23</b>

- 10 Each tablet contained paracetamol 500mg and calcium carbonate 375 mg, with ratio of calcium carbonate to paracetamol of 0.75:1

Biostudy

- 15 The following products were compared in a five way cross over pharmacokinetic study using 15 fasted healthy human volunteers:

test formula A	Tablets from Example 2
test formula B	Tablets from Example 3
test formula C	Tablets from Comparative Example A
test formula D	Commercially available swallow tablets containing paracetamol (500mg) and no sodium bicarbonate
test formula E	Commercially available soluble tablets containing paracetamol (500mg) and sodium bicarbonate (1342mg)

- 20 Each volunteer swallowed 2 tablets of one of the formulations, followed by 100mls of water on 5 separate occasions at least 48 hours apart. For test formula E, the 2 tablets were dissolved in the 100mls of water prior to swallowing. Blood samples were taken at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90, 120, 180, 240, 360, 480, and 720 minutes post dose.

Serum paracetamol levels were determined by HPLC and paracetamol serum levels vs time profiles were plotted for each volunteer. There were no significant differences in the area under the serum level vs time curve ( $AUC_{0-\infty}$ ) for any of the formulae.

- 5 The maximum concentrations of paracetamol in serum ( $C_{max}$ ) following dosing were as follows:

test formula A	30mg/L
test formula B	26mg/L
test formula C	15mg/L
test formula D	17mg/L
test formula E	20mg/L

- 10 The  $C_{max}$  for formula A was statistically significantly higher than that seen for formula C ( $p < 0.0002$ ), D ( $p < 0.002$ ) and E ( $P < 0.02$ ). There was no statistically significant difference between the  $C_{max}$  for formula A and B. The  $C_{max}$  for formula B was significantly higher than that seen for formula C ( $p < 0.01$ ) and formula D ( $p < 0.02$ )

15

The mean area under the serum concentration vs time curve between 0 and 20 minutes ( $AUC_{0-20}$ ) following dosing were derived, results were as follows:

test formula A	245 mg.min/L
20 test formula B	177 mg.min/L
test formula C	76.0 mg.min/L
test formula D	69.7 mg.min/L
test formula E	199 mg.min/L

- 25 The ( $AUC_{0-20}$ ) for formulation A was 3.5 times greater than for formulation D and the ( $AUC_{0-20}$ ) for formulation B was 2.5 times greater than for formulation D, both of these differences were statistically significant, indicating that the rate of paracetamol absorption from the invention was increased by a factor of up to 250% compared to conventional paracetamol swallow tablets.

30

**Claims**

1. A swallow tablet or capsule formulation comprising from 300mg to 600mg of paracetamol and from 300mg to 1200mg of sodium bicarbonate together with at least one pharmaceutically acceptable excipient, wherein the weight ratio of sodium bicarbonate to paracetamol is at least 0.74 to 1.
2. A formulation according to claim 1 comprising at least 370 mg of sodium bicarbonate.
3. A formulation according to claim 1 or 2 comprising no greater than 1000 mg of sodium bicarbonate.
4. A formulation according to any one of claims 1 to 3 containing 500 mg of paracetamol.
5. A formulation according to any one of claims 1 to 3 containing 325 mg of paracetamol.
6. A formulation according to any one of claims 1 to 5 wherein the weight ratio of sodium bicarbonate to paracetamol is at least 0.8 to 1.
7. A process for preparing a swallow tablet or capsule formulation as defined in any one of claims 1 to 6 which process comprises the admixture of paracetamol and sodium bicarbonate together with any pharmaceutically acceptable excipients, additional pharmaceutically acceptable active agents or adjuvants.





# INTERNATIONAL SEARCH REPORT

Int. l. Application No.

PCT/EP 98/01284

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/20 A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 377 906 A (BAYER AG) 18 July 1990 see page 4; example 2 ---	1-7
X	EP 0 418 564 A (BAYER AG) 27 March 1991 see page 3 - page 4; example 1 ---	1-3,5-7
A	DE 195 02 789 A (KRISCHENOWSKI DIRK) 1 August 1996 see column 2 - column 5 ---	1-7
A	GB 2 103 087 A (BRISTOL MYERS CO) 16 February 1983 cited in the application see page 4; example 2 -----	1-7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "G" document member of the same patent family

Date of the actual completion of the international search

25 August 1998

Date of mailing of the international search report

02/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/01284

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0377906 A	18-07-1990	US 4942039 A	17-07-1990
		CA 2007260 A,C	12-07-1990
		DE 68911501 D	27-01-1994
		DE 68911501 T	31-03-1994
		ES 2060736 T	01-12-1994
		JP 2262522 A	25-10-1990
		PT 92832 A	31-07-1990
EP 0418564 A	27-03-1991	CA 2021548 A	02-03-1991
		JP 3163016 A	15-07-1991
DE 19502789 A	01-08-1996	NONE	
GB 2103087 A	16-02-1983	AR 228661 A	30-03-1983
		AU 8436082 A	20-01-1983
		BE 893827 A	12-01-1983
		CA 1182049 A	05-02-1985
		DE 3226178 A	20-01-1983
		DK 309282 A	14-01-1983
		FR 2509174 A	14-01-1983
		JP 58023617 A	12-02-1983
		NL 8202773 A	01-02-1983
		PT 75234 B	04-10-1985
		SE 8204288 A	12-07-1982
		ZA 8203760 A	30-03-1983